Delcath reports preliminary Q3 revenue $11.2M; HEPZATO KIT sales trigger $25M warrant exercise

DELCATH SYSTEMS, INC.

2024-Q3 EPS reported -$0.84 revenue$22,105,000

Preliminary Q3 2024 revenue of $11.2M, including $10M U.S. sales from HEPZATO KIT.
Announcement of $10M U.S. quarterly revenue triggers exercise of Tranche B warrants from March 2023 PIPE.
Warrant holders have 21 days to exercise at $6/share for aggregate $25M.
Proceeds to support HEPZATO KIT commercial launch and fund new clinical trials for expanded indications.
Final Q3 results and business update scheduled for investor call on November 8, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.